Opinion
Video
Author(s):
Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.
V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76
Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
FDA Advises Against Accelerated Approval Pathway for Botensilimab/Balstilimab in R/R MSS CRC
Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma
Real-World and Post-Hoc Analyses Support Luspatercept Use in Low-Risk Myelodysplastic Syndrome
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium